Conference Coverage
Latest Content
Apr 08, 2026 | News
Wolbachia-Infected Mosquito Releases Cut Dengue Risk by Over 70% in Trial
2026 MAD-ID and SIDP Meeting: Harnessing Organizational Synergies for Clinical Education, Networking Opportunities
Apr 08, 2026
Who Will Get Tested in the Next Pandemic?
Apr 07, 2026
Early Genomic Surveillance Leads to a Decrease in Candida Auris Cases
Apr 07, 2026
Insights Around Incidence Rates and Evolving Diagnostics for Vector-Borne Diseases
Apr 06, 2026
Advertisement
Shorts
1:01
What Clinicians Must Do About Candida auris
5 days ago
by
Jatin Vyas, PhD, MD(+1 more)
0:28
Fungal Treatment: Matching Therapy to the Immune System
7 days ago
by
Jatin Vyas, PhD, MD(+1 more)
0:57
How the ACIP Has Historically Operated
18 days ago
by
Sharon Nachman, MD
0:59
What Has Happened to the ACIP in the Last Year?
19 days ago
by
Sharon Nachman, MD
0:45
Future Regulatory Reviews of COVID-19 Vaccines
20 days ago
by
Sharon Nachman, MD
1:35
When to Challenge Vaccine Messaging
21 days ago
by
Kevin Kunzmann
1:10
The Human and Healthcare Costs When People Opt Out of the MMR Vaccine
21 days ago
by
Kevin Kunzmann
0:54
SSPE: A Scary Complication of Measles
a month ago
by
Patricia A Stinchfield, RN, MS, CPNP(+1 more)
1:02
The Transmissibility of Measles
a month ago
by
Patricia A Stinchfield, RN, MS, CPNP(+1 more)
1:00
The Health Beat: Physician Frustration With CDC Measles Response
a month ago
by
Paul Offit, MD(+1 more)
Contagion: Summer 2025 Issue
View our interactive Summer 2025 issue, featuring articles on biosurveillance, aging in HIV, the NARROWS Framework for stewardship, and much more!
A Deep Dive: Understanding the Neurological Toll of Long COVID
Ravindra Ganesh, MD, MBBS, FACP, Dip ABOM, Svetlana Blitshteyn, MD, FAAN, and Monica Verduzco-Gutierrez, MD, discuss Long COVID's prevalence—noting that 1 in 5 Americans and 1 in 10 patients post-COVID may be affected.
Contribute to Contagion's Digital Book!
Contagion® is always looking for new contributors to the various sections of our book. Click to learn more about submitting.
Beyond the Virus: Long COVID’s Neurological Toll
There is increasing concern of Long COVID’s impact on the brain of patients previously infected with the virus. Featuring commentary from Jennifer Frontera, MD; Leigh Elkins Charvet, PhD; Neil Busis, MD; Alba Azola, MD; and Kristine Erlandson, MD.
COVID-19 Therapeutic Management and Prevention
Tina Tan, MD; Scott Roberts, MD; James Wilson, DO, FACP, FAWM, CTropMed; and Michael Curulewski, PharmD, BCPS, BCIDP, BCGP, discuss FDA-approved COVID-19 therapies, off-label treatments, and preventive modalities.
Podcasts
Videos
Contagion Digital Edition
Here is a case study of a patient with injection drug use, a patent foramen ovale, and recurrent MRSA bacteremia who developed rare, fatal quadruple-valve infective endocarditis involving all 4 heart valves, highlighting the high mortality risk and importance of early recognition, surgical consultation, and substance use treatment.
How stewardship teams communicate determines whether interventions feel like policing or collaboration. Using structured, data-driven frameworks— advocacy-inquiry-listen-teach and DART—creates psychological safety to explore understanding and supports shared decision-making.
Non–carbapenemase-producing carbapenem-resistant Enterobacterales (CRE) isolates are the most common mechanism of CRE in the United States,
but the optimal antimicrobial treatment remains to be elucidated.
Invasive fungal diseases remain a major cause of morbidity and mortality in patients undergoing transplant, with shifting epidemiology, emerging resistance, and geographic variation underscoring the urgent need for improved surveillance, prevention strategies, and antifungal stewardship.
The twice-yearly injectable, which significantly reduces HIV incidence compared with oral regimens, has high adherence and manageable adverse effects.
The COVID-19 pandemic intensified long-standing problems
in scientific production and communication—driven by perverse academic incentives, peer review strain, media hype, and growing misuse of AI—highlighting the urgent need for stronger critical appraisal skills across research and medicine.
The subcommittee approved the removal of doxycycline and tetracycline breakpoints, revised aminoglycoside breakpoints for Acinetobacter spp, and added aztreonam-avibactam breakpoints for Enterobacterales.
Findings from a recent study challenge the need for high-dose trimethoprim-sulfamethoxazole in managing Stenotrophomonas maltophilia pneumonia, finding lower doses may offer comparable efficacy.
A recent study examined how rurality and the availability of postdischarge follow-up influence clinicians’ decisions on antibiotic duration at discharge for patients hospitalized with community-acquired pneumonia.
A series of politically driven actions in 2025—including defunding mRNA research, dismantling vaccine advisory bodies, and restricting CDC recommendations—has undermined US vaccine access and pandemic preparedness, but professional societies and some states are stepping in to preserve evidence-based public health.
Continuing Medical Education
All News
Advertisement
Advertisement
Increased rapid antigen diagnostic testing for respiratory syncytial virus (RSV) in pediatric outpatients was associated with fewer antibiotic prescriptions for respiratory tract infections.
This week, read about omadacycline as an oral treatment option for Mycobacterium abscessus pulmonary disease, combining immunotherapy with antifungals for fungal infections, this year's Peggy Lillis Foundation's C diff meeting, and more.
The latest CDC numbers show a 6.1% increase of measles cases from week-to-week. This is a slight increase in the percentage of cases from last week where there was a 5.92% increase.
In the second part of our conversation with the Peggy Lillis Foundation’s CEO Christian Lillis, he discusses the agenda for their annual visit to Capitol Hill to advocate for the most significant issues affecting people with C diff to members of Congress.
Peggy Lillis Foundation’s annual event will have a number of speakers addressing these Clostridioides difficile (C diff)-related issues as they look to draw awareness to shortcomings in both areas as well as others. The organization's CEO Christian John Lillis offers some insights around the upcoming meeting.
Stakeholders offer some insights around the challenges and potential solutions including a federal investment in the field.
TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, offers some insights on the disease burden, and an overview of his company’s pipeline around developing a therapy for this STI.
In the final installment of the short series around fungal infections, Jatin Vyas, PhD, MD, discusses the challenges of developing antifungals.
The organization announced this year's event, which aims to bring together stakeholders in Washington, DC, to advance awareness, policy, and patient-centered solutions for Clostridioides difficile infection.
In the second installment of the short series around fungal infections, Jatin Vyas, PhD, MD, discusses the increase in Candida auris including its unique clades and past challenges in diagnosing this difficult-to-treat infection.
Advertisement
In 2018, the FDA approved omadacycline as a new oral/intravenous third generation tetracycline to treat Community Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Here is a clinical overview of omadacycline as well as recent phase 2 clinical trial results favoring oral omadacycline as an oral treatment option for Mycobacterium abscessus pulmonary disease.
Jatin Vyas, PhD, MD, discusses where the research is headed as it takes a page from the oncology world in trying to harness the immune system and combining with fungal therapeutics to treat these difficult infections.
Martin Gartland, PhD, discusses early data on the investigational therapy, VH184, including the potential for long-acting treatment and looking to address emerging drug resistance challenges.
This week, read about a new COVID variant, the test and treat paradigm model for hepatitis C, and a mission around bringing Americans with Ebola back to the US.
The latest CDC numbers show a 5.92% increase of measles cases from week-to-week. This is a decrease in the percentage of cases from last week where there was a 9.18% increase.
Advertisement
Advertisement
Trending on Contagion Live
1
Who Will Get Tested in the Next Pandemic?
2
Early Genomic Surveillance Leads to a Decrease in Candida Auris Cases
3
2026 MAD-ID and SIDP Meeting: Harnessing Organizational Synergies for Clinical Education, Networking Opportunities
4
Insights Around Incidence Rates and Evolving Diagnostics for Vector-Borne Diseases
5